Fact-checked by Grok 2 weeks ago

Paradoxical embolism

Paradoxical embolism (PDE) is a rare thromboembolic condition in which a venous bypasses the by traversing an intracardiac or intrapulmonary shunt, such as a patent foramen ovale (PFO), and enters the systemic arterial circulation, leading to acute ischemic events like , , or peripheral limb ischemia. This phenomenon, accounting for less than 2% of all arterial emboli, typically originates from deep vein thrombosis (DVT) in the lower extremities and requires a right-to-left shunt to facilitate the paradoxical passage, often triggered by transient elevations in right atrial pressure such as during Valsalva maneuvers or concurrent pulmonary embolism. The most common underlying shunt is PFO, a persistent fetal opening between the atria present in approximately 25-30% of the general population, though other defects like atrial septal defects (ASDs), ventricular septal defects, or pulmonary arteriovenous malformations can also enable PDE. A patent foramen ovale, which can enable , is present in approximately 40% to 50% of patients with cryptogenic ischemic , with an annual of about 0.1% in PFO carriers and a 1% of recurrent ; ASDs show a 2-3 times higher prevalence in females. Clinical presentation varies by the embolization site and may include sudden-onset neurological deficits (e.g., or from cerebrovascular events), suggestive of , acute limb and pain from peripheral ischemia, or abdominal symptoms from mesenteric involvement. Concurrent venous thromboembolism, such as , often coexists and heightens suspicion for PDE in patients with simultaneous arterial and venous occlusions. Diagnosis relies on a high index of suspicion, particularly in young patients with cryptogenic arterial events and risk factors for ; key modalities include to rule out arrhythmias, transthoracic or transesophageal with agitated saline bubble study to detect shunts (transesophageal being the gold standard with high sensitivity), for microembolic signals, and imaging like CT angiography or MRI to confirm and search for venous sources. Treatment is multifaceted and urgent, involving systemic anticoagulation (e.g., or direct oral anticoagulants like ) to prevent clot propagation, or for acute occlusions, and evaluation for shunt closure—percutaneous PFO closure, in addition to antiplatelet therapy, is recommended for select patients aged 18 to 60 years with a prior cryptogenic attributable to PFO, based on randomized trials including RESPECT, REDUCE, and CLOSE demonstrating reduced recurrent stroke risk compared to medical therapy alone (e.g., aspirin or ). In cases complicated by (e.g., PAI-1 mutations), guides long-term management to mitigate recurrence. Prognosis depends on the affected organ and timeliness of intervention; events carry higher morbidity and mortality, while peripheral or mesenteric cases often improve with surgical salvage, though overall in-hospital mortality can reach up to 62.5% in severe presentations without prompt therapy.

Venous Thrombus Formation

Venous thrombus formation serves as the initial step in paradoxical embolism, where a clot originates in the venous system and potentially migrates to the arterial circulation. This process is fundamentally governed by , which encompasses three key factors: , endothelial injury, and hypercoagulability. occurs when blood flow is impeded, such as during prolonged , post-surgical recovery, or in conditions like that reduce venous return. Endothelial injury arises from direct damage to the vessel wall, often due to , indwelling catheters, or invasive procedures. Hypercoagulability involves an imbalance favoring clot formation, triggered by states such as , , or use of oral contraceptives, which alter factors or platelet function. The primary sites of venous thrombi in paradoxical embolism are the deep veins of the lower extremities, where in most cases the clot originates, particularly in the iliofemoral segments. Pelvic veins also represent a significant source, with in these locations associated with a five-fold increased risk of cryptogenic compared to of known origin. These thrombi often develop subclinically, remaining undetected in more than 50% of paradoxical embolism cases, which underscores the importance of targeted for . Thrombi from these venous sites can progress to as a precursor event, fragmenting and embolizing to the lungs before any paradoxical transit occurs. Specific triggers, such as Valsalva maneuvers, may dislodge thrombi from leg veins by transiently increasing right atrial pressure, facilitating their mobilization toward potential right-to-left shunts. This progression highlights the venous system's role as the embolic source, distinct from the mechanisms enabling arterial entry.

Right-to-Left Shunt Mechanisms

Paradoxical embolism requires a that allows venous thrombi to bypass the and enter the systemic arteries. The most common intracardiac defects facilitating this are patent foramen ovale (PFO), (ASD), and (VSD). PFO, a flap-like opening between the right and left atria that fails to close after birth, is present in approximately 25% of adults and enables transient shunting under specific hemodynamic conditions. ASD involves a persistent hole in the , with secundum-type ASDs being 2 to 3 times more prevalent in females than males due to genetic and developmental factors. VSD, a defect in the ventricular , is less frequently implicated in adult paradoxical embolism but can permit shunting if right ventricular pressures exceed left, often in the context of . Pulmonary arteriovenous malformations (PAVMs), abnormal direct connections between pulmonary arteries and veins, create intrapulmonary shunts that similarly allow emboli to evade filtration, with a notable risk in . Shunting typically occurs when a transient reversal of the normal left-to-right atrial develops, directing right atrial blood—and any contained thrombi—toward the left side. This gradient inversion is often provoked by elevated right atrial pressure from acute (), which increases pulmonary vascular resistance, or by maneuvers like the Valsalva that transiently boost right-sided pressures above left-sided ones. In -associated cases, the acute obstruction heightens right ventricular , promoting interatrial shunting through PFO or in cases with coexisting defects. The probability of embolization rises with larger shunt sizes and higher right-sided pressures, underscoring the interplay between venous thromboembolic events and structural anomalies. A critical manifestation is impending paradoxical embolism, where a venous becomes lodged or straddles the shunt defect, such as a PFO, poised to dislodge into the arterial system; this "thrombus in transit" is a high-risk state often detected during acute events like massive . Such straddling thrombi highlight the dynamic nature of shunts, where partial entrapment can temporarily prevent full but signals imminent danger. Rarer extracardiac variants include intrapulmonary shunts beyond PAVMs, such as diffuse vascular abnormalities, and aortopulmonary fistulas, which create abnormal connections allowing to mix directly with arterial flow without cardiac involvement; these are infrequently reported but can precipitate paradoxical events in susceptible individuals. Overall, these mechanisms emphasize how congenital or acquired defects, combined with hemodynamic stressors, enable the rare but serious crossover of emboli from venous to arterial circulation.

Epidemiology

Incidence and Prevalence

Paradoxical embolism is a relatively rare condition, primarily manifesting as a cause of cryptogenic strokes in patients with right-to-left shunts such as (PFO). A (PFO) is identified in up to 50% of patients with cryptogenic stroke, with the annual risk of cryptogenic stroke in PFO populations estimated at approximately 0.1% and the risk of recurrent stroke at 1%. In the United States, approximately 610,000 first or new strokes occur annually, of which about 40% are cryptogenic, and 20% to 50% of these cryptogenic cases are associated with PFO, translating to an estimated 60,000 to 80,000 PFO-related cryptogenic ischemic strokes per year. Congenital cardiac defects play a central role in the prevalence of paradoxical embolism, with atrial septal defects (ASDs) accounting for 25% to 40% of all adult congenital heart disease diagnoses. PFO, a common variant, is present in 25% to 30% of the general population but is identified in approximately 70% of documented paradoxical embolism cases, often serving as the conduit for venous thrombi to enter the arterial circulation. Recent data through 2023 indicate no significant change in the overall incidence of paradoxical embolism, despite advancements in diagnostic capabilities such as , which have enhanced detection rates without altering the underlying epidemiological patterns.

Risk Factors and Demographics

Paradoxical embolism is associated with several non-modifiable risk factors, including age, with cases most commonly occurring in adults between 40 and 60 years, as evidenced by median patient ages around 45 years in clinical cohorts. Congenital right-to-left shunts, such as patent foramen ovale (PFO), exhibit familial patterns, with family history serving as a key indicator in patient evaluation. Atrial septal defects (ASDs), another congenital shunt associated with paradoxical embolism in up to 14% of ASD patients, demonstrate a female predominance, occurring 2 to 3 times more frequently in women than men. Modifiable risk factors primarily revolve around triggers for deep vein thrombosis (DVT), the precursor to paradoxical embolization, including prolonged , recent , and long-haul exceeding 4 hours, which elevate and clot formation risk. Hypercoagulable states further compound susceptibility, encompassing conditions like malignancy, inherited thrombophilias (e.g., mutation), antiphospholipid syndrome, and pregnancy-related hypercoagulability. Lifestyle factors such as smoking and obesity also contribute by promoting and prothrombotic environments. Demographically, paradoxical embolism predominantly affects adults with a prior history of venous , where the presence of a shunt amplifies risk. It shows elevated occurrence in individuals with migraines, who harbor intracardiac shunts in up to 50% of cases, suggesting a shared pathophysiological link. Certain combined risks heighten vulnerability significantly; for instance, pelvic vein thrombosis in the context of a shunt increases the odds of cryptogenic fivefold compared to other DVT sites.

Clinical Manifestations

Symptoms and Signs

Paradoxical embolism presents with a diverse array of symptoms and signs depending on the site of systemic , often mimicking other acute vascular events. The clinical manifestations arise from emboli originating in the venous system that bypass the via a , leading to ischemia in affected organs. Common associated features include evidence of concurrent deep vein thrombosis (DVT) or (PE), such as unilateral leg swelling, tenderness, warmth, , dyspnea, , and . Cerebrovascular involvement accounts for approximately 40% of cases and manifests as acute ischemic stroke or , with symptoms including sudden unilateral or weakness, or speech difficulties, seizures, deficits, facial asymmetry, and sensory disturbances. Peripheral arterial embolization, the most frequent site at about 50% of cases, typically causes acute limb ischemia characterized by the "six Ps": pain, , pulselessness, , , and poikilothermia (cold extremity). Affected patients often report sudden onset of severe limb pain, numbness, and mottled skin, with absent distal pulses on examination. Coronary artery occlusion occurs in roughly 8% of paradoxical emboli and presents with symptoms of , including substernal , , diaphoresis, , and syncope, potentially progressing to with electrocardiographic changes such as ST-segment elevation. Less common sites include renal (1%) and splenic (1%) infarctions, leading to flank or , , and elevated levels, while mesenteric involvement may cause acute abdominal ischemia with bloody , , and severe cramping pain. Non-specific symptoms such as migraines, transient syncope, or presyncope can also occur, particularly in younger patients, and may precede more overt embolic events.

Differential Considerations

Paradoxical embolism often presents with systemic , mimicking other causes of ischemic events in the , limbs, or . For cerebrovascular manifestations, such as ischemic , key differentials include cardioembolic sources like , which accounts for 14-30% of strokes and typically arises from left atrial thrombi without a venous origin. Atheroembolic stroke, stemming from atherosclerotic plaque fragmentation in large vessels, and , involving inflammatory damage to arterial walls, further complicate differentiation, as these lack evidence of a . In cases of acute limb ischemia, paradoxical embolism must be distinguished from primary arterial , often due to in situ clot formation in atherosclerotic vessels, and arterial , characterized by intimal tears leading to . , resulting from trauma-induced pressure elevation rather than embolic , represents another mimic, particularly in the lower extremities. Abdominal presentations may resemble primary mesenteric ischemia, which can be embolic (typically cardiogenic) or thrombotic, affecting the and causing without a shunt . rupture, presenting with acute abdominal pain and hemodynamic instability, also enters the differential for visceral ischemia but involves aneurysmal rather than thromboembolism. Critical discriminators for paradoxical embolism include the coexistence of deep vein thrombosis or with a confirmed , such as a patent foramen ovale, alongside systemic . It is particularly suspected in cryptogenic strokes among younger patients under 55 years, where patent foramen ovale prevalence is elevated compared to the general population. Rare mimics encompass fat embolism, often post-trauma and capable of bypassing pulmonary filtration via shunts to cause multi-organ ischemia, and , typically iatrogenic in procedural settings like insertion.

Diagnosis

In evaluating suspected paradoxical embolism, a detailed is essential to identify potential venous sources of emboli and underlying shunt mechanisms. Clinicians should inquire about prior events, including (DVT) or (PE); may be present in up to 85% of cases, with often subclinical and undetected in more than 50% of cases, and may manifest as leg swelling, pain, or calf tenderness. Recent is a key risk factor, often linked to prolonged following , long-distance travel, or , increasing the likelihood of formation in deep veins. History-taking must also explore indicators of right-to-left shunts, such as congenital heart diseases including patent foramen ovale (PFO) or , which are undiagnosed in many adults until an embolic event occurs. Migraines, especially those with , are reported in up to 50% of patients with intracardiac shunts and may suggest underlying structural abnormalities. A is particularly relevant, as individuals with PFO face an elevated risk of decompression illness from paradoxical embolization of venous nitrogen bubbles during ascent. The narrative of the acute embolic event provides critical clues, typically featuring sudden-onset systemic symptoms like ischemic stroke in young patients lacking conventional risk factors such as or . Other presentations may include acute limb ischemia with sudden and or mesenteric ischemia with , distinguishing paradoxical embolism from primary arterial sources. Comorbidities promoting hypercoagulability warrant thorough assessment, including active , , or estrogen-containing contraceptive use, all of which heighten VTE risk and potential for paradoxical passage. Family history of thrombotic disorders or congenital shunts further supports suspicion, as inherited factors like mutation contribute to a prothrombotic state. Preceding Valsalva maneuvers should be elicited, as activities like straining during , coughing, sneezing, or heavy lifting can transiently elevate right atrial pressure, facilitating transit through a shunt.

Laboratory Tests

tests play a crucial role in evaluating patients suspected of paradoxical embolism by identifying evidence of , assessing , and detecting embolic consequences on target organs. These tests help confirm the presence of deep vein (DVT) or (PE), which are often prerequisites for paradoxical embolism, while also screening for underlying hypercoagulable states and monitoring for complications such as organ ischemia. The assay is a key initial test, as it measures degradation products and is elevated in over 90% of cases involving DVT or , reflecting active and . With a of approximately 97% for , a negative D-dimer result (typically <500 ng/mL) effectively rules out thromboembolic events in low-risk patients, though its specificity is low (around 40-50%), leading to frequent false positives in conditions like or . In paradoxical embolism, where frequently coexists, an elevated quantitative plasma D-dimer supports the but requires correlation with imaging. Coagulation panels, including (PT), international normalized ratio (INR), activated partial thromboplastin time (aPTT), and fibrinogen levels, are essential to evaluate baseline before initiating anticoagulation , which is standard for paradoxical embolism . Abnormalities in these tests may indicate (DIC) in severe cases. Additionally, a thrombophilia workup is recommended to identify inherited or acquired hypercoagulable states predisposing to venous ; this includes assays for mutation, and S deficiencies, III levels, prothrombin gene mutation G20210A, elevated , and antiphospholipid antibodies (such as and ). These tests are particularly valuable in young patients without obvious risk factors, though results may be confounded by ongoing anticoagulation. Cardiac biomarkers like or T and creatine kinase-MB (CK-MB) are indicated when paradoxical embolism involves , leading to . Elevated levels (above the 99th upper reference limit, typically 14-34 ng/L for high-sensitivity assays depending on the specific test and factors) signal myocardial injury, which is more sensitive than CK-MB for detecting ischemia in this context, as seen in case series where troponin rose significantly in patients with paradoxical coronary embolism. These markers aid in risk stratification and guide urgent interventions. Renal and liver function tests, including serum , , and liver enzymes (e.g., , , ), are performed to assess for embolic damage to these organs, particularly in cases of renal or hepatic from arterial . For instance, elevated may indicate from renal emboli, while deranged liver enzymes suggest . These tests provide quantitative insight into organ involvement and help monitor therapeutic responses. A (CBC) is routinely obtained, with particular attention to platelet count, as may signal (HIT) in patients receiving for initial treatment of DVT or , or DIC in critically ill individuals with extensive embolization. HIT, an immune-mediated reaction, paradoxically increases risk despite low platelets (<150,000/μL), occurring in 0.5-5% of heparin-exposed patients and necessitating alternative anticoagulants.

Imaging Modalities

serves as the cornerstone for diagnosing right-to-left shunts in paradoxical embolism, enabling visualization of intracardiac defects and confirmation of embolic passage. with , typically using agitated saline injected into a peripheral vein, detects patent foramen ovale (PFO) by observing microbubbles crossing from the right to the left atrium, often enhanced by to increase right atrial pressure. This modality achieves a of approximately 80% for PFO detection on modern equipment, significantly outperforming standard TTE without , which misses many shunts due to limited resolution of small defects. , performed with similar , offers superior anatomical detail for visualizing atrial septal defects () and ventricular septal defects (VSD), identifying shunt size and associated thrombi with near-100% when microbubbles appear within three cardiac cycles. Vascular imaging modalities target the venous source and pulmonary involvement in paradoxical embolism. Doppler ultrasound of the lower extremities is the initial noninvasive test for deep vein (DVT), detecting thrombi in femoral and popliteal veins with high accuracy through compressibility assessment and flow velocity changes, essential for identifying the embolic origin in up to 50% of suspected cases. Computed (CT) angiography of the chest confirms (PE) by revealing filling defects in pulmonary arteries, while also assessing for arterial occlusions in systemic vessels, such as the or iliac arteries, where thrombi may straddle shunts. Imaging of embolic endpoints focuses on cerebral and peripheral consequences to evaluate ischemia and guide urgency. Noncontrast or (MRI) of the identifies acute ischemic patterns, such as multiple territorial infarcts or border-zone lesions suggestive of embolic , with diffusion-weighted MRI offering higher sensitivity for early detection within hours of onset. For limb involvement, or angiography delineates arterial occlusions causing acute ischemia, while studies, including or imaging, assess tissue viability by measuring blood flow deficits and predicting salvageable penumbra in threatened . Advanced techniques provide supplementary diagnostic and procedural support. Transcranial Doppler (TCD) ultrasonography detects microemboli in cerebral arteries as high-intensity transient signals during contrast injection, offering a sensitive (up to 97%) noninvasive screen for right-to-left shunts and ongoing , particularly in cryptogenic patients. Intracardiac echocardiography (ICE), deployed via access, delivers real-time imaging during PFO or closure procedures, confirming device positioning and residual shunting with superior resolution compared to , minimizing procedural risks.

Treatment

Acute Interventions

The acute management of paradoxical embolism prioritizes hemodynamic stabilization, prevention of recurrent embolization, and treatment of the underlying venous thromboembolism, as the condition often arises from deep vein thrombosis (DVT) or pulmonary embolism (PE) crossing a right-to-left shunt. Initial assessment involves rapid evaluation for signs of shock, hypoxia, or end-organ ischemia, with transfer to an intensive care unit (ICU) recommended for patients exhibiting hemodynamic instability. Anticoagulation forms the cornerstone of acute therapy to inhibit thrombus propagation and reduce the risk of further paradoxical events. Unfractionated heparin is typically initiated immediately via continuous intravenous infusion, with dosing adjusted to achieve an activated (aPTT) of 1.5-2.5 times the normal value, providing rapid and titratable anticoagulation. (e.g., enoxaparin) or may serve as alternatives for stable patients, offering predictable without routine monitoring. Transition to oral agents, such as direct oral anticoagulants (DOACs) like or , is preferred over antagonists (e.g., ) for most cases following initial stabilization, per guidelines for venous thromboembolism management. Contraindications to anticoagulation, such as active bleeding or recent hemorrhagic , necessitate (IVC) filter placement to prevent additional emboli from lower extremity veins. For patients with massive PE or profound hemodynamic compromise—such as systolic below 90 mmHg—systemic is indicated to accelerate clot dissolution and restore pulmonary , which indirectly mitigates the risk of paradoxical embolization. (tPA) is administered as a 100 mg intravenous bolus over 2 hours, followed by once the aPTT normalizes, though this carries a 2-6% risk of . Catheter-directed , delivering lower-dose tPA directly to the via endovascular access, is reserved for submassive PE with right ventricular dysfunction or for limb-threatening arterial ischemia to facilitate targeted reperfusion and salvage tissue. is contraindicated in the presence of hemorrhagic , recent major , or uncontrolled . Supportive measures are essential to address secondary complications and maintain organ perfusion. Supplemental oxygen is provided to correct , targeting above 90%, while intravenous fluids or vasopressors are used judiciously for , avoiding fluid overload in right ventricular strain. In refractory cases with impending circulatory collapse or failed medical , mechanical embolectomy—either surgical (open pulmonary embolectomy) or percutaneous (aspiration thrombectomy devices)—is performed to extract the clot, particularly when is contraindicated. Close monitoring in the ICU includes serial , troponin levels, and neurological assessments to detect recurrent or bleeding complications. The (AHA) and (ESC) guidelines endorse anticoagulation as the first-line acute intervention for suspected paradoxical embolism associated with DVT or , with escalation to reperfusion therapies based on risk stratification. Shunt may be considered briefly after acute stabilization in high-risk patients.

Long-Term Management

Long-term management of paradoxical embolism focuses on preventing recurrence by addressing the underlying intracardiac shunt and mitigating thrombotic risks. For patients with a patent foramen ovale (PFO), closure is the preferred approach, utilizing devices such as the Amplatzer PFO Occluder, which achieves procedural success rates exceeding 95% and effective shunt elimination in over 90% of cases. This intervention reduces the risk of recurrent ischemic stroke by 50-80% compared to medical therapy alone, as evidenced by randomized trials including and CLOSE, which demonstrated hazard ratios of 0.41 and relative risks of 0.26 for stroke recurrence in closure versus medical management groups over extended follow-up periods of up to 5 years. In cases involving atrial septal defects (ASD) or ventricular septal defects (VSD) implicated in paradoxical embolism, surgical closure is typically recommended, particularly when percutaneous options are unsuitable due to defect size or ; surgical repair yields high success rates with low recurrence of embolic events. Contraindications to percutaneous PFO closure include active infection such as or bacteremia, intracardiac masses, and unfavorable precluding safe device deployment, such as oversized defects exceeding 25 mm. Following shunt closure, antithrombotic therapy is essential for secondary prevention. Dual antiplatelet therapy with aspirin and clopidogrel is standard for 1-6 months post-procedure, transitioning to lifelong single antiplatelet therapy (e.g., aspirin 75-100 mg daily) thereafter, as recommended by guidelines to minimize recurrent . For patients with persistent risk factors such as or recurrent venous thromboembolism, long-term anticoagulation (e.g., or direct oral anticoagulants) may be indicated over antiplatelets, with annual reevaluation to assess ongoing need. Routine follow-up includes transthoracic echocardiography at 6-12 months to confirm shunt resolution and device position, with additional imaging as needed based on symptoms or risk profile. Patients should receive lifestyle counseling emphasizing stroke prevention measures, including a Mediterranean-style low in saturated fats and sodium, regular (at least 150 minutes weekly of moderate exercise), , and to address modifiable cardiovascular risks. Long-term outcomes from cohort studies indicate sustained efficacy, with ischemic event rates below 1% at over 10 years post-closure when combined with adherence to these strategies.

Prognosis and Prevention

Clinical Outcomes

Paradoxical embolism carries significant mortality risk, particularly in acute presentations. For impending paradoxical embolism, where a thrombus is detected in transit across a right-to-left shunt, the 30-day mortality rate is approximately 18.4%, as reported in a systematic review of prognostic factors. This rate rises substantially in more severe cases, reaching up to 44.7% for in-hospital mortality when an embolus is lodged in transit, and is further elevated with central nervous system involvement or multiorgan failure due to the increased incidence of ischemic stroke and systemic complications. Morbidity remains a major concern among survivors, with neurologic deficits being prominent in cases involving cerebral embolism. In patients experiencing ischemic stroke from paradoxical embolism, deficits such as hemiplegia and are common, contributing to long-term . Peripheral arterial involvement can lead to limb ischemia, which may necessitate in severe cases, while some individuals develop chronic migraines as a . Prognostic factors play a critical role in determining outcomes, with early intervention markedly improving survival and reducing complications. Prompt diagnosis and management, such as or , are essential to mitigate systemic embolization. Transcatheter of a patent foramen ovale (PFO) further enhances by lowering the annual recurrence rate of paradoxical embolism-related events to approximately 1% in most cohorts. Long-term outcomes vary by case severity, with full recovery common in uncomplicated peripheral embolism following surgical or medical intervention. In contrast, patients with cryptogenic attributed to paradoxical embolism require lifelong to detect recurrent events. Recent from 2023 indicate improved outcomes with direct oral anticoagulants (DOACs) compared to for preventing recurrent venous thromboembolism, which could precipitate further embolic episodes. Updated 2025 guidelines from the / support PFO closure in select patients with cryptogenic to reduce recurrence .

Preventive Strategies

Preventive strategies for paradoxical embolism primarily target the reduction of venous thromboembolism (VTE) risk and management of right-to-left shunts, such as patent foramen ovale (PFO), to minimize the chance of clot passage into systemic circulation. Thromboprophylaxis is essential for high-risk individuals, including those undergoing or during , where low-molecular-weight heparin (LMWH) is recommended to prevent thrombosis (DVT), a common source of paradoxical emboli. are advised to improve venous return and reduce DVT formation, particularly in patients with or prolonged immobility. In patients with known intracardiac shunts, estrogen-containing contraceptives should be avoided due to their prothrombotic effects, which can exacerbate the risk of embolism. Lifestyle modifications play a key role in lowering overall VTE risk and supporting cardiovascular health. Regular physical exercise promotes venous flow and reduces stasis, while is critical as it impairs vascular function and increases clotting tendency, especially when combined with hormonal therapies. Maintaining healthy body weight and managing comorbidities such as and through diet, medication, and monitoring further mitigate thrombotic risks associated with paradoxical embolism. Screening for right-to-left shunts is recommended in individuals with a family history of intracardiac defects or cryptogenic , using contrast-enhanced transthoracic to detect PFO or other shunts. In cases of recurrent paradoxical embolism, testing, including assays for and prothrombin gene mutations, helps identify underlying hypercoagulable states that may necessitate tailored prophylaxis. For secondary prevention, early PFO is indicated in select high-risk groups, such as patients with recurrent cryptogenic or scuba divers with prior illness, as reduces recurrent embolic events compared to medical alone. Annual follow-up with is advised for patients with congenital heart defects to monitor shunt persistence and assess for needs. Public health initiatives emphasize awareness of DVT symptoms during long-haul , such as leg swelling or , encouraging , , and use to prevent VTE that could lead to paradoxical . The 2025 ESC guidelines highlight a holistic approach to cardiovascular care, integrating thromboprophylaxis and shunt management in at-risk populations like pregnant individuals with shunts to address risks comprehensively.

References

  1. [1]
    Paradoxical Embolism - StatPearls - NCBI Bookshelf - NIH
    Sep 4, 2023 · Paradoxical embolism (PDE) occurs when a thrombus crosses an intracardiac defect into the systemic circulation.Missing: reliable | Show results with:reliable
  2. [2]
    Paradoxical embolism: a rare cause of acute upper limb ischemia
    Jul 27, 2023 · Paradoxical emboli are defined by the passage of venous embolic material into the arterial circulation through a cardiac shunt [2].Missing: reliable | Show results with:reliable
  3. [3]
    Contemporary Approach to Paradoxical Embolism | Circulation
    May 6, 2014 · Three recent studies provide, for the first time, data from prospective, randomized trials to guide treatment in patients with PFO and paradoxical embolism.Missing: reliable | Show results with:reliable
  4. [4]
    Case Report: Perhaps we can do more when paradoxical embolism ...
    Aug 11, 2025 · Paradoxical Embolism (PDE) is a rare thromboembolic disease with a high mortality rate, which can reach 62.5% within the first 24 h (2). PDE is ...Missing: reliable sources<|control11|><|separator|>
  5. [5]
    Virchow Triad - StatPearls - NCBI Bookshelf
    Jun 7, 2024 · Vascular thrombi are formed in low flow and shear stress, mainly consisting of fibrin strands, red blood cells, and a few platelets.
  6. [6]
    Paradoxical Embolism: Practice Essentials, Pathophysiology, Etiology
    Apr 7, 2023 · DVT may be subclinical in more than 50% of cases. Venous thrombosis may occur in more than 50% of orthopedic surgical procedures and more than ...Practice Essentials · Pathophysiology · Etiology · Epidemiology
  7. [7]
    Increased pelvic vein thrombi in cryptogenic stroke - PubMed
    Cryptogenic patients had more MRV scans with a high probability for pelvic DVT (20%) than patients with stroke of determined origin (4%, P<0.03), with most ...
  8. [8]
    Paradoxical Embolism Workup - Medscape Reference
    Apr 7, 2023 · By increasing RAP, a Valsalva maneuver or cough could potentially dislodge an entrapped thrombus. Impending PDE may result in a false ...
  9. [9]
    Management of Patent Foramen Ovale - US Cardiology Review (USC)
    Oct 9, 2017 · However, based on several large autopsy studies, approximately 25 % of healthy adults in the general population have a patent foramen ovale ( ...<|separator|>
  10. [10]
    Atrial Septal Defects in the Adult | Circulation
    Oct 10, 2006 · ASDs are common and can present at any age. Females constitute 65% to 75% of patients with secundum ASDs, but the gender distribution is equal ...
  11. [11]
    Pulmonary Arteriovenous Malformations - ATS Journals
    Jul 10, 2014 · Paradoxical emboli lead to strokes and cerebral abscesses, and these commonly occur in individuals with previously undiagnosed PAVMs. PAVM ...Clinical Features of PAVM. · New Insights into PAVM Ph. · Management Strategies
  12. [12]
    Impending paradoxical embolism? Report of four clinical cases and ...
    Thrombus straddling the patent foramen ovale (TSFO) is a rare event. It occurs in the presence of pulmonary embolism and can be responsible for paradoxical ...
  13. [13]
    Intracardiac versus extracardiac shunt in a young man with ...
    Mar 8, 2022 · On the other hand, intrapulmonary shunts, a form of extracardiac shunting, are rare but recognised cause of paradoxical emboli. Hereby, we ...Missing: aortopulmonary | Show results with:aortopulmonary
  14. [14]
    Paradoxical Embolism | Circulation
    Nov 9, 2010 · Paradoxical embolism, or venous thromboembolism transit from right- to left-sided cardiac chambers, may occur via interventricular, interatrial, or pulmonary ...
  15. [15]
    Cryptogenic Stroke and Patent Foramen Ovale - JACC
    Feb 26, 2018 · In people who suffer a cryptogenic stroke, 40% to 50% of patients have a PFO (1–3). A hypermobile septum primum, referred to as an atrial septal ...
  16. [16]
    Stroke Facts - CDC
    Oct 24, 2024 · ... stroke decreased from 39.5 per 100,000 in 2022 to 39.0 per 100,000 in 2023.1; Every 40 seconds, someone in the United States has a stroke.2 ...
  17. [17]
    Are Patients with a Patent Foramen Ovale at Increased Risk of ...
    These findings indicate that 60,000 to 80,000 cryptogenic ischemic strokes per year in the US occur in patients with a PFO. The increased prevalence of PFOs in ...
  18. [18]
    Atrial Septal Defect in Adulthood - American College of Cardiology
    Jul 29, 2022 · ASD is the most common congenital heart disease diagnosed in adulthood, accounting for 25-30% of diagnoses.
  19. [19]
    Epidemiology of Patent Foramen Ovale in General Population and ...
    Apr 28, 2020 · According to our review, PFO prevalence in the general population across all ages was roughly 24% in autopsy and TEE studies. As expected, this ...
  20. [20]
    JoS : Journal of Stroke
    Sep 26, 2023 · Despite this, it is estimated that PFO is likely responsible for approximately 5% of all ischemic strokes and 10% of those occurring in young ...
  21. [21]
    Contrast-Enhanced Transcranial Doppler for Detecting Residual ...
    The study population included 75 cases: 41 females (55%) and 34 males (45%), aged 18–77 years (median 45 years, IQR 35–53 years). The study group's risk profile ...2. Materials And Methods · 2.2. Pfo Closure Procedure · 2.4. Occluder Size Selection
  22. [22]
    Ischemic stroke in the young: Current perspectives on incidence, risk ...
    This review provides an overview of recent data on epidemiology, risk factors, and their strength of association in ischemic stroke in the young.
  23. [23]
    The Risk of Paradoxical Embolism (RoPE) Study - PubMed Central
    The goal of the Risk of Paradoxical Embolism (RoPE) Study is to develop and test a set of predictive models that can identify those patients most likely to ...Missing: demographics | Show results with:demographics
  24. [24]
    Paradoxical Embolism Clinical Presentation - Medscape Reference
    Apr 7, 2023 · Physical Examination · Unilateral leg swelling, tenderness, warmth, and erythema. Palpable cord along the course of the affected veins (possible).
  25. [25]
    Impending Paradoxical Embolism | JAMA Internal Medicine
    Thus, provocative maneuvers, such as Valsalva or cough, could potentially dislodge an entrapped thrombus; however, no cases of this phenomenon have been ...
  26. [26]
    Paradoxical Embolism - JACC
    Jul 21, 2014 · Paradoxical embolism refers to the clinical phenomenon of thromboembolism originating in the venous vasculature and traversing through an ...Missing: reliable | Show results with:reliable
  27. [27]
    Paradoxical Embolism Differential Diagnoses - Medscape Reference
    Apr 7, 2023 · Differential Diagnoses · Atrial Fibrillation · Deep Venous Thrombosis (DVT) · Infective Endocarditis · Primary Cardiac Neoplasms · Septic ...Missing: limb | Show results with:limb
  28. [28]
    Clinical features and diagnosis of acute arterial occlusion of the ...
    Feb 10, 2025 · - Paradoxical embolism ... Vascular imaging · DIFFERENTIAL DIAGNOSIS · Chronic limb ischemia · Acute compartment syndrome · Phlegmasia · Others.<|separator|>
  29. [29]
    Acute Mesenteric Ischemia - StatPearls - NCBI Bookshelf - NIH
    An acute mesenteric arterial embolism is often cardiogenic in origin and primarily affects the superior mesenteric artery (SMA). Preceding events include atrial ...
  30. [30]
    Patent Foramen Ovale and Cryptogenic Stroke in Older Patients
    A meta-analysis showed that the presence of patent foramen ovale in patients younger than 55 years of age is significantly associated with cryptogenic stroke.
  31. [31]
    Recurrent Decompression Illness Even After the Closure of Patent ...
    Dec 8, 2022 · Therefore, those authors suggested that PFO plays a key role in the paradoxical embolization of venous nitrogen bubbles after SCUBA diving.
  32. [32]
    Value of D-dimer levels for the diagnosis of pulmonary embolism - NIH
    Jun 15, 2018 · Using CTPA as the gold standard, D-dimer had a sensitivity of 96.2%, a specificity of 50.0%, a positive predictive value of 89.3%, a negative ...
  33. [33]
    Systematic review and meta-analysis of test accuracy for the ...
    Sep 11, 2020 · The pooled estimates for D-dimer sensitivity and specificity were 0.97 (95% CI, 0.96-0.98) and 0.411 (95% CI, 0.36-0.46), respectively. Figure 2 ...Abstract · Introduction · Methods · Results
  34. [34]
    Cardiac Biomarkers in Pulmonary Embolism - CHEST Journal
    The circulating troponin level indicates irreversible myocardial cell damage and is much more sensitive than creatine kinase (CK) or CK-MB levels. The ...
  35. [35]
    Paradoxical Coronary Artery Embolism - A Rare Cause of ... - PMC
    Cardiac biomarkers were elevated (Troponin-T 2.230 ng/ml (normal <0.01 ng/ml) ... A diagnosis of ST elevation myocardial infarction secondary to paradoxical ...
  36. [36]
    Paradoxical Embolism Leading to Myocardial Infarction - JACC
    Oct 8, 2025 · The differential diagnosis included deep venous thrombosis (DVT), acute limb ischemia, pulmonary embolism, paradoxical embolism, acute coronary ...
  37. [37]
    Renal infarction caused by paradoxical embolism through a patent ...
    Paradoxical embolism is a rare cause of renal infarction, but immediate recognition of a paradoxical embolus is very important so that anticoagulation or device ...
  38. [38]
    A Case Report on Paradoxical Emboli - Archives of Vascular Medicine
    Oct 17, 2024 · Initial lab results revealed a creatinine level of 1.16 mg/dL (baseline of 1.24 mg/dL), mildly elevated liver enzymes, and leukocytosis with a ...
  39. [39]
    Heparin-induced thrombocytopenia | Blood - ASH Publications
    May 25, 2017 · Heparin-induced thrombocytopenia (HIT) is an immune complication of heparin therapy caused by antibodies to complexes of platelet factor 4 (PF4) and heparin.
  40. [40]
    A “Catastrophic” Heparin-Induced Thrombocytopenia - PMC - NIH
    Apr 13, 2020 · HIT is a potential life-threatening disease characterized by a decrease in platelet count and thrombosis after heparin exposure. ... A third type ...
  41. [41]
    Comparison of transthoracic echocardiography with harmonic ... - NIH
    Patent foramen ovale can be diagnosed by bubble contrast TTE and TOE on modern echo machines with a sensitivity of about 80%. Pitfalls of TTE include quality of ...
  42. [42]
    Paradoxical Embolism Detected on CT Angiography and Treated ...
    Paradoxical embolism is a rare disease occurring in patients with pulmonary embolism or venous thrombosis through a right-to-left shunt, such as the patent ...
  43. [43]
    Paradoxical Embolism: Role of Imaging in Diagnosis and Treatment ...
    Oct 13, 2014 · Paradoxical embolism (PDE) is an uncommon cause of acute arterial occlusion that may have catastrophic sequelae. The possibility of its ...Missing: reliable | Show results with:reliable
  44. [44]
    Patent Foramen Ovale Size and Embolic Brain Imaging Findings ...
    Patent foramen ovale (PFO) has long been recognized as a potential risk factor for ischemic stroke through paradoxical cerebral embolism (PCE). Case ...
  45. [45]
    MRI in the Evaluation of Cryptogenic Stroke and Embolic Stroke of ...
    Apr 23, 2024 · MRI is a valuable modality for the etiologic work up in patients with cryptogenic stroke and embolic stroke of undetermined source.<|separator|>
  46. [46]
    Transcranial Doppler–Detected Microemboli in Patients With Acute ...
    Background and Purpose Transcranial Doppler sonography (TCD) has been used to detect microembolic signals in a variety of clinical situations.
  47. [47]
    Patent Foramen Ovale: Going Beyond the Bubbles - JACC
    Mar 17, 2014 · The sensitivity of TCD for the diagnosis of intracardiac left-to-right shunt was 97%, with specificity of 93%; as expected, an increase in ...
  48. [48]
    Intracardiac echocardiography in the diagnosis and closure of ... - NIH
    This study was intended to summarize some aspects of PFO. We placed particular focus on the application of ICE in PFO diagnosis and closure.
  49. [49]
    Paradoxical Embolism Treatment & Management
    Apr 7, 2023 · Treatment of paradoxical embolism (PDE) involves medical intervention, surgical intervention, or both. The presence of PDE in association ...
  50. [50]
    Interventional Therapies for Acute Pulmonary Embolism
    Oct 4, 2019 · The purpose of this document is to clarify the current state of endovascular interventional therapy for acute PE and to provide considerations ...
  51. [51]
    Transcatheter Patent Foramen Ovale Closure in Stroke Patients with ...
    Sep 30, 2022 · Factor V Leiden and prothrombin gene mutation may predispose to paradoxical embolism in subjects with patent foramen ovale. Blood Coagul ...<|separator|>
  52. [52]
    Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets ...
    Sep 14, 2017 · The rate of effective PFO closure (defined as no or minimal residual shunt at follow-up echocardiography) in our trial (93.0%) was similar to ...
  53. [53]
    Patent Foramen Ovale Management for Secondary Stroke Prevention
    Nov 21, 2023 · A patent foramen ovale (PFO) is a congenital heart abnormality resulting from the failed closure of the antenatal interatrial communication and ...
  54. [54]
    Long-Term Outcomes of Patent Foramen Ovale Closure or Medical ...
    Sep 14, 2017 · Closure of a PFO was associated with a lower rate of recurrent ischemic strokes than medical therapy alone during extended follow-up.
  55. [55]
    Patent foramen ovale closure versus medical therapy after ...
    Patent foramen ovale closure in adults with recent cryptogenic stroke was associated with a lower rate of recurrent strokes in comparison with medical therapy ...
  56. [56]
    Surgical Treatment of Atrial Septal Defects - PMC - PubMed Central
    Sep 29, 2024 · Surgical repair yields excellent outcomes for all ASD subtypes, with minimally invasive approaches, especially in adults, increasingly employed for ASD closure.
  57. [57]
    Catheter Management of Patent Foramen Ovale - StatPearls - NCBI
    [6] In addition to indications and contraindications for PFO closure, every practitioner should be aware of the common post-op complications; arrhythmia is the ...
  58. [58]
    Antithrombotic therapy in patients with patent foramen ovale (PFO ...
    Oct 1, 2023 · Dual antiplatelet therapy (aspirin and clopidogrel) should be given for 1–6 months after PFO closure followed by single antiplatelet therapy for ...Summary · Patient selection and treatment... · Antithrombotic therapy after...
  59. [59]
    Navigating the Uncertainties of Antithrombotic Therapy After ... - NIH
    After a median follow‐up of 5.9 years, closure of PFO was associated with a lower rate of recurrent ischemic stroke than medical therapy (3.6% vs. 5.8%, p ...
  60. [60]
    SCAI Guidelines for the Management of Patent Foramen Ovale
    May 19, 2022 · SCAI expert consensus statement on operator and institutional requirements for PFO closure for secondary prevention of paradoxical embolic ...
  61. [61]
    2021 Guideline for the Prevention of Stroke in Patients With Stroke ...
    May 24, 2021 · Lifestyle factors, including healthy diet and physical activity, are important for preventing a second stroke. Low-salt and Mediterranean diets ...
  62. [62]
    Long-Term Follow-Up After Closure of Patent Foramen Ovale in ...
    Jan 21, 2019 · The results of this study showing the low stroke rate >10 years post-PFO closure support the long-term efficacy and safety of this treatment for ...
  63. [63]
    Impending paradoxical embolism: systematic review of prognostic ...
    Results: Thirty-day mortality was 18.4%. On univariate analysis, age (64+/-13.9 vs 56.7+/-16.5; P = .01), coma (12.9% vs 2.2%; P = .
  64. [64]
    Paradoxical Embolus Stuck in a Patent Foramen Ovale - PubMed
    In-hospital mortality rate of an embolus in transit is as high as 44.7%. In some cases, a paradoxical embolus can get stuck in a patent foramen ovale.
  65. [65]
    Risk of ischemic stroke in patients with pulmonary embolism and ...
    Patent foramen ovale is a common condition in patients with acute PE and is associated with a higher incidence of ischemic stroke and increased mortality.Missing: rates | Show results with:rates<|separator|>
  66. [66]
    Paradoxical Embolism Is an Unusual Etiology of Acute Limb ...
    Jun 20, 2023 · PFOs exist in 15-35% of the adult population and most commonly manifest as cerebrovascular accidents. However, recent reports suggest that the ...
  67. [67]
    An Unusual Case of Cannula Obstruction Resulting From Venous ...
    Despite optimal management, IPDE is associated with a mortality rate of 18%. Prompt diagnosis and treatment is critical in avoiding systemic thromboembolization ...
  68. [68]
    Recurrent events after percutaneous closure of patent foramen ovale
    Oct 1, 2013 · After PFO closure, the annual rate of events potentially related to paradoxical embolism was 0.14% (9 events in 6,211 patient-years).Missing: prognosis | Show results with:prognosis
  69. [69]
    Patent Foramen Ovale Closure in Older Patients With Cryptogenic ...
    Previous studies involving patients older than 55 years who underwent transcatheter PFO closure reported a recurrent stroke rate of <1 per 100 patient-years ...
  70. [70]
    Clinical Outcomes of Direct Oral Anticoagulants vs Warfarin for ... - NIH
    Aug 15, 2023 · These findings suggest that compared with warfarin, DOAC treatment is associated with a lower risk of recurrent VTE in patients taking extended anticoagulation ...Missing: paradoxical | Show results with:paradoxical<|control11|><|separator|>
  71. [71]
    Thromboembolism in Pregnancy Treatment & Management
    Jun 6, 2025 · For antepartum outpatient prophylaxis, treatment-dose LMWH or UFH is recommended for women with a clinical history of multiple VTE episodes, VTE ...Medical Care · Low Molecular Weight Heparin... · Prevention
  72. [72]
    [PDF] Percutaneous closure of patent foramen ovale for the secondary ...
    Dec 15, 2010 · Percutaneous closure of PFO for the secondary prevention of recurrent paradoxical embolism in divers is carried out with the patient under local.Missing: guidelines | Show results with:guidelines
  73. [73]
    Patent Foramen Ovale Closure for Nonstroke Indications
    Use of PFO closure as a treatment for migraines appears to be most promising in patients with frequent aura or those who are responsive to P2Y12 inhibitors.
  74. [74]
    Deep Vein Thrombosis and Pulmonary Embolism | Yellow Book - CDC
    Apr 23, 2025 · Travelers with a recent PE may travel after ≥5 days if anticoagulation is stable and the partial pressure of oxygen (PAO2) is normal on room air ...Missing: paradoxical | Show results with:paradoxical
  75. [75]
    [PDF] 2025 ESC Guidelines for the management of cardiovascular ...
    Aug 31, 2025 · a risk of paradoxical air embolism (i.v. line filters should be used for. i.v. therapies). Thromboembolism is a major risk, and ...